WASHINGTON, D.C. — The U.S. Food and Drug Administration has approved expanded use of the drug Wellcovorin for patients with a rare genetic neurological disorder, providing the first FDA-approved treatment for cerebral folate deficiency linked to the FOLR1 gene.
What This Means for You
- The FDA approved Wellcovorin for patients with a rare genetic condition affecting folate transport to the brain.
- The treatment is approved for both adults and children with confirmed FOLR1 gene variants.
- The decision marks the first FDA-approved therapy for this rare neurological disorder.
The drug, also known as leucovorin calcium, is now approved for treating cerebral folate deficiency associated with a variant in the folate receptor 1 gene, often referred to as CFD-FOLR1.
Understanding Cerebral Folate Deficiency
Cerebral folate deficiency is a neurological condition that disrupts the transport of folate — a vitamin essential for brain development and function — into the brain.
Patients with the condition can experience severe developmental delays, seizures, movement disorders, and other neurological complications.
Until now, there had been no FDA-approved treatment specifically for the condition.
“Today’s approval represents a significant milestone for patients living with cerebral folate transport deficiency due to the FOLR1 variant,” said FDA Commissioner Dr. Marty Makary. “This action may benefit some individuals with FOLR1-related cerebral folate transport deficiency who have developmental delays with autistic features.”
Approval Based on Published Research
Unlike many drug approvals that rely primarily on large clinical trials, the FDA said this approval was based on a systematic review of existing medical literature.
That review included published case reports with patient-level information as well as biological and mechanistic research explaining how the drug works in the body.
The agency said the available evidence demonstrated clinical benefit for patients with the condition.
Tracy Beth Hoeg, acting director of the FDA’s Center for Drug Evaluation and Research, said the approval reflects the agency’s approach to evaluating treatments for rare diseases.
“The approval of leucovorin for FOLR1-related cerebral folate transport deficiency demonstrates the FDA’s commitment to rapidly identifying effective treatments for ultra rare diseases while maintaining the same evidentiary standards for approval,” Hoeg said.
Collaboration With Drug Manufacturer
The FDA worked with GSK, the manufacturer and holder of the drug’s New Drug Application, to update the product labeling to include guidance on its use for patients with the FOLR1-related condition.
The updated labeling provides clinical information intended to help physicians prescribe the medication safely and effectively for both pediatric and adult patients.
Potential Side Effects
As with many medications, leucovorin may cause side effects.
Reported side effects include itching, rash, hives, breathing difficulties, chills accompanied by shivering, and irregular body temperature regulation.
In rare cases, patients may experience anaphylaxis, a severe allergic reaction that requires immediate medical treatment.
Next Steps
The FDA said the approval addresses a critical treatment gap for patients living with cerebral folate deficiency and reflects ongoing efforts to expand therapies for rare genetic diseases.
More information about the approval is available in the FDA’s supplemental approval documentation.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.